New hope for tough lymphoma: antibody combo targets cancer after CAR t fails

NCT ID NCT07003295

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 7 times

Summary

This phase II trial tests two antibodies, glofitamab and obinutuzumab, in 20 people with mantle cell lymphoma that has returned or not responded after CAR T-cell therapy. Glofitamab helps T cells attack cancer by binding to both T cells and lymphoma cells, while obinutuzumab blocks cancer growth. The study aims to see if this combination is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glofitamab (a bispecific antibody) and obinutuzumab (a monoclonal antibody)
What this could lead to: If this works, it could offer a new treatment option for people with mantle cell lymphoma that has come back or not responded after CAR T-cell therapy.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatment may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT MANTLE CELL LYMPHOMA REFRACTORY MANTLE CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Case Western Reserve University
RECRUITING

Cleveland, Ohio, 44106, United States

Contact Email: •••••@•••••
City of Hope Comprehensive Cancer Center
RECRUITING

Duarte, California, 91010, United States

Contact Email: •••••@•••••
Emory Saint Joseph's Hospital
RECRUITING

Atlanta, Georgia, 30342, United States
Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITING

Baltimore, Maryland, 21287, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
UPMC Hillman Cancer Center
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Vanderbilt University/Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.